Simvastatin treatment prevents oxidative damage to DNA in whole blood leukocytes of dyslipidemic type 2 diabetic patients

Cell Biochemistry and Function

Volumn 28, Issue 5, 2010, Pages 360-366

  Manfredini, Vanusa ^a,b   Biancini, Giovana Brondani ^c   Vanzin, Camila Simioni ^c   Dal Vesco, Anna Maria Ribeiro ^b,c   Cipriani, Franciele ^a   Biasi, Lidiana ^b   Treméa, Roberta ^b   Deon, Marion ^a,c   Ruaro Peralba, Maria Do Carmo ^a   Wajner, Moacir ^a,c   Vargas, Carmen Regla ^a,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b DEPARTMENT OF FOOD ENGINEERING   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

C reactive protein; Comet assay; Dyslipidemic type 2 diabetes; Paraoxonase; Statins

Indexed keywords

ARYLDIALKYLPHOSPHATASE; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MALONALDEHYDE; REACTIVE OXYGEN METABOLITE; SIMVASTATIN;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; COMET ASSAY; CONTROLLED STUDY; DIABETES MELLITUS; DNA DAMAGE; DYSLIPIDEMIA; ENZYME ACTIVITY; FEMALE; HUMAN; LEUKOCYTE; LIPID PEROXIDATION; MACROMOLECULE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; BLOOD; COMPLICATION; CONTROLLED CLINICAL TRIAL; DRUG EFFECTS; DYSLIPIDEMIAS; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADULT; AGED; ARYLDIALKYLPHOSPHATASE; C-REACTIVE PROTEIN; COMET ASSAY; DIABETES MELLITUS, TYPE 2; DNA DAMAGE; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKOCYTES; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; SIMVASTATIN;

EID: 77956848196     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1654     Document Type: Article

References (72)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995- 2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-1431.
2. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-412.
3. Solano MP, Goldberg RB. Lipid management in type 2 diabetes. Clin Diabetes 2006; 24: 27-32.
4. NavabM, Berliner JA,Watson AD, et al. The yin and yang of oxidation in the development of the fatty streak: A review based on the 1994 george lyman duff memorial lecture. Arterioscler Thromb Vasc Biol 1996; 16: 831-842.
5. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-795.
6. Griesmacher A, Kindhauser M, Andert SE, et al. Enhanced serum levels of thiobarbituric acid- reactive substances in diabetes mellitus. Am J Med 1995; 98: 469-475.
7. Telci A, Çakatay U, Kayali R, et al. Oxidative protein damage in plasma of type 2 diabetic patients. Horm Metab Res 2000; 32: 40-43.
8. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine, 3rd ed. Oxford University Press: New York, 2007.
9. Bartsch H, Nair J. Ultrasensitive and specific detection methods for exocylic DNA adducts: Markers for lipid peroxidation and oxidative stress. Toxicology 2000; 153: 105-114.
10. Barter PJ, Rye KA. Molecular mechanisms of reverse cholesterol transport. Curr Opin Lipidol 1996; 7: 82-87.
11. Brewer HB Jr. High-density lipoproteins: A new potential therapeutic target for the prevention of cardiovascular disease. Arterioscler Thromb Vasc Biol 2004; 24: 387-391.
12. Ansell BJ, Watson KE, Fogelman AM, et al. High density lipoprotein function. Recent advances. J Am Coll Cardiol 2005; 46: 1792-1798.
13. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res 2006; 98: 1352-1364.
14. Negre-Salvayre A, Dousset N, Ferretti G, et al. Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic Biol Med 2006; 41: 1031-1040.
15. Mackness MI, Harty D, Bhatnagar D, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86: 193-199.
16. Shih DM, Gu L, Xia YR, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394: 284-287.
17. Rozenberg O, Shih DM, Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: Studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 2005; 181: 9-18.
18. Shih DM, Xia YR, Wang XP, et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 2000; 275: 17527-17535.
19. Tward A, Xia YR, Wang XP, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002; 106: 484-490.
20. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscl Thromb Vasc Biol 1995; 15: 1812-1818.
21. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-154.
22. Inoue M, Suehiro T, Nakamura T, Ikeda Y, Kumon Y, Hashimoto K. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism 2000; 49: 1400-1405.
23. Patel BN, Mackness MI, Harty DW, et al. Serum esterase activities and hyperlipidaemia in the streptozotocin-diabetic rat. Biochim Biophys Acta 1990; 1035: 113-116.
24. Iwase M, Kazuo S, Nobuhiro S, et al. Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: Relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment. Atherosclerosis 2008; 196: 931-936.
25. Baldassarre S, Scruel O, Deckelbaum RJ, Dupont IE, Ducobu J, Carpentier YA. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin. Int J Cardiol 2005; 104: 338-345.
26. Karatepe M. Simultaneous determination of ascorbic acid and free malondialdehyde in human serum by HPLC-UV. LCGC North Am 2004; 22: 362-365.
27. Lissi E, Salim-Hanna M, Pascual C, et al. Evaluation of total antioxidant potential (TRAP) and total antioxidant reactivity from luminolenhanced chemiluminescence measurements. Free Radic Biol Med 1995; 18: 153-158.
28. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988; 175: 184-191.
29. Bajpayee M, Pandey AK, Parmar D, Dhawan A. Current status of shortterm tests for evaluation of genotoxicity, mutagenicity, and carcinogenicity of environmental chemicals and NCEs. Toxicol Mech Methods 2005; 15: 155-180.
30. Hartmann A, Agurell E, Beevers C, et al. Recommendations for conducting the in vivo alkaline comet assay. Mutagenesis 2003; 18: 45-51.
31. Tice RR, Agurell E, Anderson D, et al. Single cell gel/comet assay: Guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 2000; 35: 206-221.
32. Maluf SW, Erdtmann B. Follow-up study of the genetic damage in lymphocytes of pharmacists and nurses handling antineoplastic drugs evaluated by cytokinesis-block micronuclei analysis and single cell gel electrophoresis assay. Mutat Res 2000; 471: 21-27.
33. Nadin S, Vargas-Roig L, Ciocca D. A silver staining method for singlecell gel assay. J Histochem Cytochem 2001; 49: 1183-1186.
34. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase polymorphism: Identification of phenotypes by their response to salts. Am J Hum Genet 1983; 35: 214-227.
35. Chakraborti T, Ghosh SK, Michael JR, et al. Targets of oxidative stress in the cardiovascular system. Mol Cell Biochem 1998; 187: 1-10.
36. Stadtman ER, Berlett BS. Reactive oxygen-mediated protein oxidation in ageing and disease. Drug Metab Rev 1998; 30: 225-243.
37. Ambrosio G, Tritto I. Reperfusion injury: Experimental evidence and clinical implications. Am Heart J 1999; 138: 69-75.
38. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis 2000; 21: 361-370.
39. Fridlyand LE, Philipson LH. Reactive species and early manifestation of insulin resistance in type 2 diabetes. Diab Obes Metab 2006; 8: 136-145.
40. Sastre J, Pallardó FV, García De La Asunción J, Viña J. Mitochondria, oxidative stress and aging. Free Radic Res 2000; 32: 189-198.
41. Cipollone F, Fazia ML, Mezzetti A. Oxidative stress, inflammation and atherosclerotic plaque development. Int Congr Ser 2007; 1303: 35-40.
42. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 1999; 85: 753-766.
43. Franzoni F, Quinones-Galvan A, Regoli F, et al. A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol 2003; 90: 317-321.
44. Marz W, Wieland H. HMG-CoA reductase inhibition: Anti-inflammatory effects beyond lipid lowering? Herz 2000; 25: 117-125.
45. Vaughan JC, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348: 1079-1082.
46. Girona J, La Ville AE, Sola R, et al. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 1999; 83: 846-851.
47. Bellosta S, Ferri N, Arnaboldi L, Bernini F, Paoletti R, Corsini A. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care 2000; 23: B72-B78.
48. Kearney D, Fitzgerald D. The anti-thrombotic effects of statins. J Am Coll Cardiol 1999; 33: 1305-1307.
49. Skrha J, Stulc T, Hilgertova J, et al. Effect of simvastatin and fenofibrate on endothelium in type 2 diabetes. Eur J Pharmacol 2004; 493: 183-189.
50. Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999; 26: 892-904.
51. Speit G, Hartmann A. The contribution of excision repair to the DNA effects seen in the alkaline single cell gel test (comet assay). Mutagenesis 1995; 10: 555-559.
52. Shin M-J, Cho EY, Jang Y, et al. A beneficial effect of simvastatin on DNA damage in 242T allele of the NADPH oxidase p22phox in hypercholesterolemic patients. Clin Chim Acta 2005; 360: 46-51.
53. Lodovici M, Giovannelli L, Pitozzi V, Bigagli E, Bardini G, Rotella CM. Oxidative DNA damage and plasma antioxidant capacity in type 2 diabetic patients with good and poor glycaemic control. Mutat Res 2008; 638: 98-102.
54. Collins AR, Raslova K, Somorovska M, et al. DNA damage in diabetes: Correlation with a clinical marker. Free Radic Biol Med 1998; 25: 373-377.
55. Dandona P, Thusu K, Cook S, et al. Oxidative damage to DNA in diabetes mellitus. Lancet 1996; 347: 444-445.
56. Rosenblat M, Vaya J, Shih DM, et al. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: A possible role for lysophosphatidylcholine. Atherosclerosis 2005; 179: 69-77.
57. Dincer Y, Aldemir Z, IIkova H, et al. Susceptibility of glutathione and glutathione related antioxidant activity to hydrogen peroxide in patients with type 2 diabetes: Effect of glycemic control. Clin Biochem 2002; 35: 295-301.
58. Mackness B, Durrington PN, Abuashia B, et al. Low paraoxonase activity in type 2 diabetes mellitus complicated by retinopathy. Clin Sci 2000; 98: 355-363.
59. Letellier C, Durou MR, Jouanolle AM, Le Gall JY, Poirier JY, Ruelland A. Serum paraoxonase activity and paraoxonase gene polymorphism in type 2 diabetic patients with or without vascular complications. Diabetes Metab 2002; 28: 297-304.
60. Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: Relevance to diabetes. Atherosclerosis 2006; 187: 74.e1, 74.e10.
61. Tsuzura S, Ikeda Y, Suehiro T, et al. Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes. Metabolism 2004; 53: 297-302. (Pubitemid 38684688)
62. Fuhrman B, Volkova N, Aviram M. Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low-density lipoprotein in macrophages from atherosclerotic mice: Protective role of antioxidants and of paraoxonase. Atherosclerosis 2002; 161: 307-316.
63. Rozenberg O, Shih DM, Aviram M. Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: Possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation. Arterioscler Thromb Vasc Biol 2003; 23: 461-467.
64. Onat A, Can G, Hergenç G. Serum C-reactive protein is an independent risk factor predicting cardiometabolic risk. Metab Clin Exp 2008; 57: 207-214.
65. Albert MA, Danielson E, Rifai N, Ridker PM, et al. Effect of statin therapy on C-reactive protein levels : The pravastatin inflammation/ CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001; 286: 64-70.
66. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933-1935
67. Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol 1999; 19: 2894-2900.
68. Weber C, Erl W, Weber KSC, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b- dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997; 30: 1212-1219.
69. Murphy RT, Foley JB, Mulvihill N, Crean P, Walsh MJ. Impact of preexisting statin use on adhesion molecule expression in patients presenting with acute coronary syndromes. Am J Cardiol 2001; 87: 446-448.
70. Aviram M, Dankner G, Cogan U, Hochgraf E, Brook JG. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: In vitro and in vivo studies. Metab Clin Exp 1992; 41: 229-235.
71. Wagner AH, Kohler T, Rückschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20: 61-69.
72. Laaksonen R, Jokelainen K, Laakso J, et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and highenergy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996; 77: 851-854.